Panke E S, Yang L I, Leist P A, Magevney P, Fry R J, Lee R F
Molecular Diagnostics Center, Good Samaritan Hospital, Cincinnati, Ohio 45220-2489.
J Clin Microbiol. 1991 May;29(5):883-8. doi: 10.1128/jcm.29.5.883-888.1991.
A 2-h nonisotopic DNA probe assay for the direct detection of Neisseria gonorrhoeae in urogenital specimens has recently been modified (PACE 2; Gen-Probe, San Diego, Calif.). The new assay format was developed to increase the sensitivity of the assay and simplify procedural steps. In this study, the new DNA probe test was compared with a culture reference method for the detection of N. gonorrhoeae in endocervical specimens. The results of the DNA probe test were expressed as a ratio of relative light units (RLU) of the specimen/RLU of the cutoff recommended by the manufacturer. All patient samples with sample RLU/cutoff RLU ratios less than 0.7 were interpreted as negative, and ratios greater than 2.0 were interpreted as positive for gonorrhea. Samples with sample RLU/cutoff RLU ratios between 0.7 and 2.0 were repeated until two or more consistent negative or positive ratios were obtained. A total of 469 specimens were tested with an overall disease prevalence of 6.1%. Of the 469 patients tested, 5 specimens (1.0%) fell in this borderline region and were retested. If the manufacturer's recommended cutoff value had been used, the original DNA probe results would have resulted in two false-positives. Our data were analyzed for both symptomatic (prevalence, 11.7%) and asymptomatic (prevalence, 2%) women. The study indicated that with our modification of the manufacturer's endpoint interpretation, the DNA probe test was essentially equivalent to the culture method in terms of sensitivity, specificity, and positive and negative predictive values in both symptomatic and asymptomatic patient populations. The new DNA probe test can serve as a suitable screening and diagnostic test for the diagnosis of gonorrheal genital infections in women. Additionally, it offers the advantages of rapid turnaround time and ease of use and allows simultaneous testing for Chlamydia trachomatis on the same specimen.
一种用于直接检测泌尿生殖系统标本中淋病奈瑟菌的2小时非同位素DNA探针检测法最近已得到改进(PACE 2;基因探针公司,加利福尼亚州圣地亚哥)。开发新的检测形式是为了提高检测的灵敏度并简化操作步骤。在本研究中,将新的DNA探针检测法与一种用于检测宫颈标本中淋病奈瑟菌的培养参考方法进行了比较。DNA探针检测结果以标本的相对光单位(RLU)/制造商推荐的临界值的RLU之比表示。所有标本RLU/临界值RLU之比小于0.7的患者样本被判定为阴性,比值大于2.0的样本被判定为淋病阳性。标本RLU/临界值RLU之比在0.7至2.0之间的样本需重复检测,直到获得两个或更多一致的阴性或阳性比值。共检测了469份标本,总体疾病患病率为6.1%。在检测的469名患者中,有5份标本(1.0%)落在这个临界区域并进行了重新检测。如果使用制造商推荐的临界值,原始DNA探针检测结果会导致两例假阳性。我们对有症状(患病率11.7%)和无症状(患病率2%)的女性的数据进行了分析。研究表明,通过我们对制造商终点解释的改进,DNA探针检测法在有症状和无症状患者群体的灵敏度、特异性以及阳性和阴性预测值方面与培养法基本相当。新的DNA探针检测法可作为诊断女性淋病性生殖器感染的合适筛查和诊断检测方法。此外,它具有周转时间短和使用方便的优点,并且允许在同一份标本上同时检测沙眼衣原体。